Organophosphorus compounds: Classification and enzyme reactions;Organofosforni spojevi: Klasifikacija i reakcije s enzimima

Arhiv za Higijenu Rada i Toksikologiju

Volumn 57, Issue 4, 2006, Pages 445-457

  Bosak, Anita ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Glutathion S transferase; Monooxygenase; Phosphoric triester hydrolases; Serine esterases

Indexed keywords

ACETYLCHOLINESTERASE; CARBOXYLESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; GLUTATHIONE TRANSFERASE; ORGANOPHOSPHATE PESTICIDE; ORGANOPHOSPHORUS COMPOUND; PHOSPHORUS; SULFUR; UNSPECIFIC MONOOXYGENASE;

BIOTRANSFORMATION; CHOLINESTERASE INHIBITION; COVALENT BOND; ENZYME INHIBITION; ENZYME MECHANISM; NEUROTRANSMISSION; REVIEW;

ORGANOPHOSPHORUS COMPOUNDS;

EID: 33845918032     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Costa LQ, Toby BC, Vitalone A, Furlong CE. Measurements of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity Clin Chim Acta 2005;352:37-47.
2. U.S. Environmental Protection Agency (US EPA). Pesticides: Organophosphates [pristup 10. srpnja 2006.]. Dostupno na http://www.epa.gov./ pesticides/op/gov.
3. Maceljski M, Hrlec G, Ostojić Z, Cvjetković B. Pregled sredstava za zaštitu bilja u Hrvatskoj. Glasnik zaštite bilja 2000;3-4:127-209.
4. Fest C, Schmidt KJ, urednici. The Chemistry of Organophosphorus Pesticides. 2nd ed. Berlin: Springer-Verlag; 1982.
5. Eto M. Organophosphorus pesticides: Organic and Biological Chemistry. Clevelend: CRC Press, Inc.; 1974.
6. Krieger R, urednik. Handbook of Pesticide Toxicology. 2nd ed. San Diego (CA): Academic Press Inc.; 2001.
7. Gupta R, urednik. Toxicology of Organophosphate and Carbamate Compounds. San Diego (CA): Elsevier Academic Press; 2006.
8. Price B. Brief nomenclature review: phosphate, phosphonate, phosphorous, phosphorus. The ASA Newsletter 2001;82(01-1):7.
9. Chambers JE, Levi PE, urednici. Organophosphates: Chemistry, Fate and Effects. San Diego (CA): Academic Press Inc., 1992.
10. Rapić V. urednik. Vodič kroz IUPAC-ovu nomenklaturu organskih spojeva, Preporuke IUPAC 1993., Preporuke HKD i HDKI 2001. Zagreb: Školska knjiga; 2002.
11. Leigh GJ, urednik. Simeon VI, urednik hrvatskog prijevoda. Hrvatska nomenklatura anorganske kemije, Preporuke IUPAC 1990. i HKD 1995. Zagreb: Školska knjiga; 1996.
12. Benschop HP, De Jong LPA. Toxicokinetics of nerve agents. U: Somani SM, Romano Jr JA, urednici. Chemical warfare agents: toxicity at low levels. Boca Raton: CRC Press; 2000. str. 25-74.
13. International Union of Biochemistry and Moleular Biology (IUBMB). Enzyme Nomenclature EC 3.1.1.5 [pristup 26. srpnja 2006]. Dostupno na 〈http://www. chem.qmul.ac.uk/iubmb/enzyme/EC3/1/1/5.html〉.
14. Enzyme Nomenclature, Recommendations of the Nomenclature Comitee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes. San Diego (CA): Academic Press Inc.; 1992.
15. Soreq H, Seidman S. Acetylcholinesterase: new roles for an old actor. Neuroscience 2001;2:294-301.
16. Adler M, Manley HA, Purcell AL, Deshpande SS, Hamilton TA, Kan RK, Oyler G, Lockridge O, Duysen EG, Sheridan RE. Reduced acetylcholine receptor density, morphological remodeling, and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice. Muscle Nerve 2004;33:317-27.
17. Aldridge WN, Reiner E, urednici. Enzyme Inhibitors as Substrates: Interaction of Esterases with Esters of Organophosphorus and Carbamatic Acids. Amstrdam: North-Holland; 1972.
18. Maroni M, Colosio C, Ferioli A, Fait A. Biological monitoring of pesticide exposure: a review. Toxicology 2000;143:5-118.
19. Giacobini E, urednik. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz Ltd.; 2000.
20. Glynn P. NTE: one target protein for different toxic syndromes with distinct mechanisms? BioEssays 2003;25:742-5.
21. Van Tienhoven M, Atkins J, Li Y, Glynn P. Human neurophathy target esterase catalyzes hydrolysis of membrane lipids. J Biol Chem 2002;277:20942-8.
22. Johnson MK. Sensitivity and selectivity of compounds interacting with neurophaty tyrget esterase, Further structure-activity studies. Biochem Pharmacol 1988;37:4095-104.
23. Glynn P. Neural development and neurodegeneration: two faces of neurophathy target esterase. Prog Neurobiol 2000;61:61-74.
24. Reiner E, Davis CS, Schwab BW, Schopfer LM, Richardson RJ. Kinetics of heat inactivation of phenyl valerate hydrolases from hen and rat brain. Biochem Pharmacol 1987;36:3181-5.
25. Jokanović M. Biotransformation of organophosphorus compounds. Toxicology 2001;166:139-60.
26. Hartleib J, Rüterjans H. High-yield expression, purification, and characterisation of the recombinant diisopropylfluorophosphatase from Loligo vulgaris. Protein Expres Purif 2001;21:210-9.
27. Hartleib J, Rüterjans H. Insights into the reaction mechanism of the diisopropylfluorophosphatase from Loligo vulgaris by means of kinetic studies, chemical modification and site-directed mutagenesis. Biochim Biophis Acta 2001;1546:312-24.
28. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khershonsky O, Meged R, Dvir H, Ravelli RBG, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-9.
29. Hoskin FCG. An organophosphorus detoxifying enzyme unique to squid. U: Gilbert DL, Andelman JWJ, Arnold JM, urednici. Squid as experimental animals. New York: Plenum Press; 1990. str. 469-80.
30. Draganov DI, La Du BN. Pharmacogenetics of paraoxonase: a brief review. Arch Pharmacol 2004;369:78-88.
31. Bargota RS, Akhtar M, Biggadike K, Gani D, Allemann RK. Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors. Bioorg Med Chem Lett 2003;13:1623-6.
32. Costa LG, Toby BC, Vitalone A, Furlong FC. Paraoxonase polymorphysms and toxicity of organophosphates. U: Gupta R, urednik. Toxicology of organophosphate and carbamate compounds. San Diego (CA): Elsevier Academic Press; 2006. str. 247-57.
33. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am J Hum Genet 2001;8:1428-36.
34. Geldmacher-von Mallinckrodt M, Diepgen TL. Human serum paraoxonase-polymorphism, specificity, classification. U: Reiner E, Aldridge Wn, Hoskin FCG, urednici. Enzymes hydrolysing organophosphorus compounds. Chichester: Ellis Horwood Limited; 1989. str. 15-30.
35. Reiner E, Simeon-Rudolf V, Škinjarić-Špoljar M. Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Toxicol Lett 1995;82/83:447-52.
36. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusisi AJ, Furlong CE. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 2000;10:767-79.
37. Hoskin FCG, Kirkish MA, Steinmann KE. Two enzymes for the detoxication of organophosphorus compounds-sources, similarities, and significance. Fund Appl Toxicol 1984;4:165-72.
38. Raushel FM. Bacterial detoxication of organophosphate nerve agents. Curr Opin Microbiol 2002;5:288-95.
39. Russell AJ, Berberich JA, Drevon GF, Koepsel RR. Biomaterials for mediation of chemical and biological warfare agents. Annu Rev of Biomed Eng 2003;5:1-27.
40. Gopal S, Rastogi V, Ashman W, Mulbry W. Mutagenesis of organophosphorus hydrolase to enhance hydrolysis of the nerve agent VX. Biochem Biophys Res Commun 2000;279:516-9.
41. Cheng T-C, Harvey SP, Stroup AN. Purification and properties of a highly active organophosphorus acid anhydrolase from Alteromonas undina. Appl Environ Microbiol 1993;59:3138-40.
42. International Union of Biochemistry and Moleular Biology (IUBMB). Enzyme Nomenclature EC 1.14.14.1 [pristup 29. rujna 2006]. Dostupno na http://www. chem.qmul.ac.uk/iubmb/enzyme/EC1/14/14/1.html.
43. International Union of Biochemistry and Moleular Biology (IUBMB). Enzyme Nomenclature EC 1.14.13.8 [pristup 29. rujna 2006]. Dostupno na http://www. chem.qmul.ac.Uk/iubmb/enzyme/EC1/14/13/8.html.
44. Levi PE, Hodgson E. Stereospecificity in the oxidation of phorate sulphoxide by purified FAD-containing mono-oxygenase and cytochrome P-450 isozymes. Xenobiotica 1988;18:29-39.
45. Monov A, Diskovsky C, urednici. Medical aspects of chemical and biological terrorism. Chemical terrorism and traumatism. Sofia: House of the Union of scientists in Bulgaria; 2005.
46. Fukuto TR, Metcalf RL. Metabolism of insectides in plants and animals. Ann NY Acad Sci 1969;160:97-113.
47. Omiecinski CJ, Remmel RP, Hosagrahara VP. Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci 1999;48:151-6.
48. Baker EL, Warren M, Zack M, Dobbin RD, Miles JW, Miller S, Alderman L, Teeters WR. Epidemic malathion poisoning in Pakistan malaria workers. Lancet 1978;1(8054):31-4.
49. Reiner E, Pleština R. Regeneration of cholinesterase in humans and rats after inhibition by O,O-dimethyl-2,2-dichlorovinyl phosphate. Toxicol Appl Pharmacol 1979;49:451-4.
50. Reiner E, Krauthacker B, Simeon V, Škrinjarić- Špoljar M. Mechanism of inhibition in vitro of mammilian acetylcholinesterase and cholinesterase in solutions of O,O-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (trichlorphon). Biochem Pharmacol 1975;24:717-22.
51. Reiner E. Esterases in schistosomes: reaction with substrates and inhibitors. Acta Pharmacol Toxicol 1981;49:72-8.
52. World Health Organisation (WHO). Schistosomiasis [pristup 10. srpnja 2006.]. Dostupno na http://www. who.int/mediacentre/factsheets/fs115/en/indeks. html.
53. Giacobini E. Cholinesterases in human brain: the effect of cholinesterase inhibitrs on Alzheimer's disease and related disorders. U: Giacobini E, Pepeu G, urednici. The brain cholinergic system in health and disease. Abingdon: Informa Healthcare; 2006. str. 235-64.
54. Doctor BP, Raveh L, Wolf AD, Maxwell DM, Ashani Y. Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci Behav Rev 1991;15:123-8.
55. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev Res 2000;50:298-308.
56. Amitai Q, Gaidukov L, Adani R, Yishay S, Yacov G, Kushnir M, Teitelboim S, Lindenbaum M, Bel P, Khershonsky O, Tawfik DS, Meshulam H. Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBS J 2006;273:1906-19.
57. Kovarik Z, Radić Z, Berman HA, Simeon-Rudolf V, Reiner E, Taylor P. Mutant cholinesterases possessing enhanced capacity for reactivation of their phosphonylated conjugates. Biochemistry 2004;43:3222-9.
58. Amitai G, Adani R, Hershkovitz M, Bel P, Rabinovitz I, Meshulam H. Degradation of VX and mustard by enzymatic haloperoxidatin. J Appl Toxicol 2003;23:225-33.
59. Amitai G, Adani R, Sod-Moriah G, Rabinowitz I, Vincze A, Leader H, Chefetz B, Leibovitz-Persky L, Friesem D, Hadar Y. Oxidative biodegradation of phosphorothiolates by fungal laccase. FEBS Lett 1998;438:195-200.